Floatz logo

7-((3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO(C,F)(1,2)THIAZEPIN-11-YL)AMINO)HEPTANOIC ACID S,S-DIOXIDE

Treatment Resistant Depression

Jonathan A. Javitch, MD, PhDSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

235 Active assets in the Treatment Resistant Depression cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

7-((3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO(C,F)(1,2)THIAZEPIN-11-YL)AMINO)HEPTANOIC ACID S,S-DIOXIDE is also rated in:

major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
bipolar disorderDormant
CCC
Indicative ·
54 / 100
View asset →
Post-mastectomy Pain SyndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →